Company news
Castle Biosciences, Inc. (NASDAQ:CSTL) news
Every Castle Biosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Castle Biosciences Reports Second Quarter 2026 Results
July 30, 2026
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
July 22, 2026
CoastalSouth Bancshares, Inc. Reports Earnings for Second Quarter 2026
July 20, 2026
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
July 14, 2026
Castle Biosciences : to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
July 9, 2026
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
July 9, 2026
Castle Biosciences : DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph...
June 25, 2026
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
June 25, 2026
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
June 23, 2026
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
June 16, 2026
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
May 13, 2026
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
May 12, 2026
Castle Biosciences Reports First Quarter 2026 Results
May 6, 2026
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
May 5, 2026
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus
May 4, 2026
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence ...
April 21, 2026
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
April 15, 2026
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
April 10, 2026
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Ali...
March 27, 2026
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Crit...
March 13, 2026
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients...
March 9, 2026
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely A...
March 4, 2026
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
March 3, 2026
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
February 26, 2026
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faste...
February 19, 2026
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
February 5, 2026
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
January 11, 2026
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2025
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Surviva...
December 17, 2025
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patien...
December 12, 2025
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
December 9, 2025
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
November 17, 2025
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positi...
November 14, 2025
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
November 11, 2025
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Der...
November 3, 2025
Castle Biosciences Reports Third Quarter 2025 Results
November 3, 2025
Castle Biosciences to Participate in Upcoming Investor Conferences
October 28, 2025
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clini...
October 26, 2025
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented ...
October 24, 2025
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
October 13, 2025
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
October 1, 2025
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
September 23, 2025
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
September 17, 2025
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients N...
September 9, 2025
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cuta...
August 25, 2025
Castle Biosciences Reports Second Quarter 2025 Results
August 4, 2025
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
July 29, 2025
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
July 25, 2025
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
July 23, 2025
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
July 17, 2025